Want to see NUTX full AI Analyst Report?
EarningsQ2 2026 Earnings Report
NUTX Q2 2026 EPS Results
Actual EPS$9.38
Consensus EPS$4.95
Beat/MissBeat by +$4.43
One Year Ago EPS-$2.95
NUTX Q2 2026 Revenue Results
Actual Revenue$210.75M
Expected Revenue$215.03M
Beat/MissMissed by -$4.28M
YoY Revenue Growth-21.30%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
NUTX Upcoming Earnings
Clinigence Holdings's next earnings date is estimated for November 24, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
NUTX Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized multiple meaningful operational and financial positives: a large jump in net income driven by lower non-cash/one-time expenses (notably stock-based compensation swing), stronger adjusted EBITDA and operating income, cash-flow improvement, meaningful cost reductions tied to the HaloMD amendment and a CMS IDR fee cut, sustained patient-volume growth and an active de novo development pipeline. Offsetting these positives were declines in reported revenue year-over-year (largely explained by prior-period IDR catch-up effects), higher G&A as a percent of revenue, and slower-than-desired insurer behavior and contract progress. On balance, the scale and persistence of the liquidity, profitability, arbitration cost savings, and volume improvements outweigh the revenue comparability headwinds and insurer uncertainties.Company Guidance
Sharp Increase in Net Income
Net income attributable to Nutex increased to $112.6 million for the first half of 2026, a 3,100% increase from $3.5 million in the same period of 2025. Q2 net income was $65.8 million versus a Q2 2025 net loss of $17.7 million (increase of $83.5 million).
Improved Adjusted EBITDA and Operating Income
Adjusted EBITDA for the first half of 2026 rose to $147.5 million (up 2.2% from $144.4 million). Q2 adjusted EBITDA increased 25.7% to $90.0 million from $71.6 million. Operating income for the 6 months increased to $203.0 million from $114.3 million (increase of $88.6 million).
Stronger Cash Position and Operating Cash Flow
Cash and cash equivalents grew to roughly $205–207 million as of June 30, 2026 (up ~10% vs year-end 2025). Net cash from operating activities increased 40% to $109.7 million for the first half of 2026 versus $78.2 million in 2025.
Volume Growth and Same-Hospital Momentum
Total hospital visits for the first 6 months were 99,704, up 6.2% from 93,842 in H1 2025. Q2 hospital division visits increased 9.6% to 49,962, and same-hospital visits grew 6.3% in Q2 and 3.4% for the first half, reflecting operational execution and higher acuity.
Significant Arbitration/IDR Cost Reductions
Q2 contract services decreased by about $52 million driven by (1) CMS reducing the IDR administrative fee from $115 to $15 (≈$4.3M benefit in Q2) and (2) a HaloMD amendment shifting to a pay-on-collected structure (≈$38.4M benefit) plus favorable service-fee changes (~$9.6M). Management expects a ~25%–30% reduction in normalized contract services costs going forward and arbitration cost rates moving into the high-teens to low-20s percentage range.
Population Health and Service Line Expansion
Population Health revenue increased ~15% for the first half to $17.8 million (Q2 revenue ~$8.9M, +16%). The division manages nearly 40,000 patients. The company launched endoscopy services and continues to expand service lines and IPA networks to drive referrals and retention.
Development Pipeline and Growth Capacity
Nutex expects three hospitals (West Little Rock, San Antonio, Jacksonville) to open in Q3–Q4 2026 and a 2027 pipeline across Florida and Oklahoma. Company strategy supports 3–5 new hospital openings per year and increased internalization of real estate development to control timelines and costs.
Operational and Patient-Experience Strengths
Gross profit margin improved (Q2 gross profit $141.3M = 67% of revenue vs 51.2% prior-year quarter). Patient satisfaction remains high with an average Google rating of 4.8 across >2,300 reviews, and employee turnover was low at 6.8% for the first half of 2026.
Favorable Arbitration Outcomes and Collection Metrics
Nutex submits ~50%–60% of claims through IDR, prevails in over 85% of determinations, and collects on over 80% of determination wins—supporting recovery and revenue realization from dispute resolution activity.
NUTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed